Sydney Lupkin Sydney Lupkin is the pharmaceuticals correspondent for NPR.
Stories By

Sydney Lupkin

Sydney Lupkin

Pharmaceuticals Correspondent

Sydney Lupkin is the pharmaceuticals correspondent for NPR.

She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.

Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.

Story Archive

Rep. Mariannette Miller-Meeks, R-Iowa, listens as Robert Kramer, president and chief executive officer of Emergent BioSolutions, testifies during a Wednesday hearing of the House Select Subcommittee on the Coronavirus Crisis. Pool/Getty Images hide caption

toggle caption
Pool/Getty Images

Patents Are Just One Piece Of The Global Vaccine Manufacturing Problem

  • Download
  • <iframe src="https://www.npr.org/player/embed/994396185/994400658" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

U.S. Backs Waiving International Patent Protections For COVID Vaccines

  • Download
  • <iframe src="https://www.npr.org/player/embed/994145450/994145451" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Doses of the Johnson & Johnson COVID-19 vaccine will drop by 86% next week after one of the company's manufacturers released a stockpile and those have been distributed. Michael M. Santiago/Getty Images hide caption

toggle caption
Michael M. Santiago/Getty Images

States Will Have 86% Fewer Johnson & Johnson Doses Next Week Than It Did This Week

  • Download
  • <iframe src="https://www.npr.org/player/embed/985860435/985860436" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Johnson & Johnson Vaccine Batch Ruined At Baltimore Factory, Drug Giant Says

  • Download
  • <iframe src="https://www.npr.org/player/embed/983314948/983314949" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Moncef Slaoui, seen last November in the White House Rose Garden, was a key figure in the Trump administration's crash program to develop COVID-19 vaccines. Mandel Ngan/AFP via Getty Images hide caption

toggle caption
Mandel Ngan/AFP via Getty Images

In a February visit to Pfizer's Kalamazoo, Mich., manufacturing complex, President Biden said the administration had "used the Defense Production Act to speed up the supply chain for ... key equipment, like fill pumps and filters, which has already helped increase vaccine production." Evan Vucci/AP hide caption

toggle caption
Evan Vucci/AP

Defense Production Act Speeds Up Vaccine Production

  • Download
  • <iframe src="https://www.npr.org/player/embed/976531488/976785294" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

President Biden inspects COVID-19 vaccine freezers at a Pfizer plant in Kalamazoo, Mich., with White House Coronavirus Response Coordinator Jeffrey Zients, Michigan Gov. Gretchen Whitmer and Pfizer CEO Albert Bourla on Feb. 19. Brendan Smialowski/AFP via Getty Images hide caption

toggle caption
Brendan Smialowski/AFP via Getty Images

Moderna And Pfizer On Track To Hit Vaccine Production Goals

  • Download
  • <iframe src="https://www.npr.org/player/embed/976172231/976199493" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

Moderna And Pfizer Are On Track To Hit Vaccine Targets

  • Download
  • <iframe src="https://www.npr.org/player/embed/976166880/976166881" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

There Will Be Enough Vaccine Doses For Every US Adult By May, Biden Says

  • Download
  • <iframe src="https://www.npr.org/player/embed/973410820/973433221" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Normally Competitors, Merck To Produce Vaccines For Johnson & Johnson

  • Download
  • <iframe src="https://www.npr.org/player/embed/972970840/972970841" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Pharmaceutical giant Merck will help manufacture Johnson & Johnson's COVID-19 vaccine. Alex Gottschalk/DeFodi Images via Getty Images hide caption

toggle caption
Alex Gottschalk/DeFodi Images via Getty Images

Acting FDA Commissioner Janet Woodcock said the agency would likely hold advisory panel meetings to consider changes in COVID-19 vaccines made in response to coronavirus variants. Scott Hensley/NPR hide caption

toggle caption
Scott Hensley/NPR

FDA Aims To Be 'Nimble' On COVID-19 Vaccine Changes For Variants

  • Download
  • <iframe src="https://www.npr.org/player/embed/966510470/966678340" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

With Coronavirus Variants On The Rise, Vaccine Companies And FDA Pivot

  • Download
  • <iframe src="https://www.npr.org/player/embed/966498583/966500994" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript